---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017810"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:28:48.800755+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity

## Summary
- ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.
- Agent commission set at 3.0% of gross proceeds; sales at prevailing market prices on Nasdaq.
- Company has no obligation to sell any shares; agreement terminates upon full sale or earlier termination.
- Offering registered under existing S-3 shelf (File No. 333-279718); prospectus supplement filed July 3, 2025.

## SEC filing metadata
- accession: 0001641172-25-017810
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000164117225017810/0001641172-25-017810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000164117225017810/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017810
- JSON: https://secwatch.observer/filing/0001641172-25-017810.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.